tiprankstipranks
Trending News
More News >

Taysha Gene Therapies price target raised to $8 from $6 at Needham

Needham raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps a Buy rating on the shares after Taysha last week reported updated clinical data from the adult/pediatric REVEAL studies and details on an FDA-aligned pivotal study. Evidence of dose-dependence is further de-risking for TSHA-102 and the firm views this update as “a win across the board,” the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue